Overview

Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

Summary

The aim of the present study is to evaluate the 24h bronchodilatory efficacy of inhaled aclidinium bromide 400 µg administered twice a day versus placebo and tiotropium bromide, respectively, after 6 weeks of treatment.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Bromides
Tiotropium Bromide